Does Rallies show 13F holders for RYTM?

Yes. Rallies tracks hedge fund and 13F ownership data for RYTM, including fund names, share counts, latest tracked quarter, and position changes when available.

Is RYTM research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RYTM. It does not provide personalized investment advice.

RYTM (Rhythm Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a publicly traded Healthcare sector company. As of May 21, 2026, RYTM trades at $90.54 with a market cap of $5.95B and a P/E ratio of -28.53. RYTM moved +3.78% today. Year to date, RYTM is -11.02%; over the trailing twelve months it is +41.91%. Its 52-week range spans $45.91 to $122.20. Analyst consensus is strong buy with an average price target of $137.64. Rallies surfaces RYTM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RYTM stock?

Hedge funds tracked by Rallies that own RYTM include Orbimed Advisors, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rhythm Pharmaceuticals, Inc. Common Stock.

RYTM Key Metrics

Key financial metrics for RYTM
Metric	Value
Price	$90.54
Market Cap	$5.95B
P/E Ratio	-28.53
EPS	$-3.13
Dividend Yield	0.00%
52-Week High	$122.20
52-Week Low	$45.91
Volume	600
Avg Volume	0
Revenue (TTM)	$217.16M
Net Income	$-202.68M
Gross Margin	89.41%

Top Hedge Funds Holding RYTM

Orbimed Advisors holds 314.10K shares of RYTM, changed +30.98% as of Mar 31, 2026.
Panagora Asset holds 64.61K shares of RYTM, changed -45.91% as of Sep 30, 2025.
Centerbook Partners holds 9.03K shares of RYTM, changed +0.00% as of Mar 31, 2026.

Latest RYTM News

Rhythm Pharmaceuticals jumps after Q1 revenue beat and new IMCIVREE obesity approvals — May 6, 2026
Rhythm Pharma rallies on Q1 IMCIVREE sales beat and fast HO launch uptake — May 5, 2026
Rhythm Pharma Sees 5% Q1 Sales Growth to $60.1M, Wins EU Nod, Targets Japan H2 — May 5, 2026
Rhythm Pharma rises ahead of May 5 earnings after recent IMCIVREE label expansion — May 4, 2026
Setmelanotide Shows 16.4% BMI Cut and 71.1% Weight-Category Gains in Pediatric Trial — May 4, 2026

Recent RYTM Insider Trades

German Christopher Paul sold 5.61K (~$502.79K) on Mar 4, 2026.
Smith Hunter C sold 1.31K (~$131.15K) on Feb 19, 2026.
Smith Hunter C sold 1.69K (~$170.75K) on Feb 19, 2026.

RYTM Analyst Consensus

14 analysts cover RYTM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $137.64.

Common questions about RYTM

Who owns RYTM stock?: Hedge funds tracked by Rallies that own RYTM include Orbimed Advisors, Panagora Asset, and Centerbook Partners. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Rhythm Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for RYTM?: Yes. Rallies tracks hedge fund and 13F ownership data for RYTM, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RYTM research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RYTM. It does not provide personalized investment advice.